CoQ10 / Ubiquinol
Lipid-soluble cofactor in the mitochondrial electron transport chain (Complex I, II, III). Critical for ATP synthesis. Also acts as lipid-phase antioxidant protecting against mitochondrial membrane peroxidation.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Endogenous CoQ10 declines with age and is depleted by statins (HMG-CoA reductase inhibition also blocks mevalonate pathway upstream of CoQ10 synthesis). Most compelling evidence is in heart failure (reduced ejection fraction improves in Q-SYMBIO trial) and statin-induced myopathy mitigation. Cognitive data is preliminary. Ubiquinol (reduced form) has higher bioavailability than ubiquinone — especially meaningful in older populations where conversion of ubiquinone → ubiquinol declines.
Blood thinner interaction: CoQ10 may reduce warfarin efficacy — monitor INR if anticoagulated. Blood pressure: mild antihypertensive effect (5–10 mmHg systolic) — beneficial for most, but monitor if already hypotensive.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Dietary supplement (DSHEA). Not FDA-approved for any indication. Q-SYMBIO trial data used in European heart failure guidelines.
Distilled themes from named communities — Reddit threads, forums, creator commentary. Not direct quotes; not clinical evidence. Useful for calibrating expectations against what real self-experimenters report.
Near-universally included in longevity stacks. Statin users report subjective reduction in muscle fatigue/cramping. High heterogeneity in response to ubiquinone vs ubiquinol by age — most >50 report better response to ubiquinol.